Education
About Us
Working with TipRanks
Follow Us
LakeShore Biopharma (LSBCF)
OTHER OTC:LSBCF
LSBCF Stock Chart & Stats
$0.85
--
Market closed
$0.85
--
Day’s Range― - ―
52-Week Range$0.06 - $2.80
Previous CloseN/A
VolumeN/A
Average Volume (3M)5.12K
Market Cap
$2.65M
Enterprise Value$404.52M
Total Cash (Recent Filing)$246.35M
Total Debt (Recent Filing)$424.46M
Price to Earnings (P/E)―
Beta0.83
Next Earnings
Apr 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding41,212,692
10 Day Avg. Volume4,144
30 Day Avg. Volume5,120
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)3.80
Price to Sales (P/S)3.09
P/FCF Ratio-13.69
Enterprise Value/Market Cap152.41
Enterprise Value/Revenue0.70
Enterprise Value/Gross Profit1.04
Enterprise Value/Ebitda-1.29
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained gross margins above 75% indicate strong product economics and pricing power for LakeShore’s therapies. Over 2–6 months this margin base supports ability to fund R&D per unit revenue, absorb COGS inflation, and provides structural leverage if revenues scale and operating losses narrow.
Rare-disease / Complex-disease FocusA strategic focus on rare and complex diseases aligns with durable industry tailwinds: regulatory incentives, higher per-patient pricing, and lower competition. This supports long-term licensing, milestone and royalty economics and makes partnerships and deal-based funding more attainable over months to years.
Improving Leverage TrendAn improving debt-to-equity trend signals better leverage management and incremental restoration of financial flexibility. Over the medium term, reduced leverage pressure can lower refinancing risk, free capacity for R&D funding or partnerships, and improve creditor and partner confidence.
Bears Say
Negative Operating And Free Cash FlowPersistent negative operating and free cash flows create a structural liquidity drain that constrains runway, forces reliance on external financing or milestones, and limits the company’s ability to advance clinical programs without dilutive capital or strategic partner funding in the coming months.
Large Arbitral Awards And Fraud ProbeMaterial arbitration awards plus an ongoing fraudulent litigation investigation create sustained legal and financial overhang. Potential cash outflows and governance questions can deplete resources, impede partner deals, and raise uncertainty around management credibility and balance sheet resilience.
Going-private Deal UncertaintyThe buyer’s MAE claim and EGM postponement inject structural uncertainty into corporate strategy and capital structure. Delay or collapse of the going‑private transaction affects access to committed funding, governance clarity, and timing of strategic execution for months ahead.
LakeShore Biopharma News
LSBCF FAQ
What was LakeShore Biopharma’s price range in the past 12 months?
LakeShore Biopharma lowest stock price was $0.06 and its highest was $2.80 in the past 12 months.
What is LakeShore Biopharma’s market cap?
LakeShore Biopharma’s market cap is $2.65M.
When is LakeShore Biopharma’s upcoming earnings report date?
LakeShore Biopharma’s upcoming earnings report date is Apr 17, 2026 which is in 47 days.
How were LakeShore Biopharma’s earnings last quarter?
Currently, no data Available
Is LakeShore Biopharma overvalued?
According to Wall Street analysts LakeShore Biopharma’s price is currently Overvalued.
Does LakeShore Biopharma pay dividends?
LakeShore Biopharma does not currently pay dividends.
What is LakeShore Biopharma’s EPS estimate?
LakeShore Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does LakeShore Biopharma have?
LakeShore Biopharma has 41,212,692 shares outstanding.
What happened to LakeShore Biopharma’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of LakeShore Biopharma?
Currently, no hedge funds are holding shares in LSBCF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
LakeShore Biopharma
LakeShore Biopharma Co., Ltd, a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was formerly known as YS Biopharma Co., Ltd. and changed its name to LakeShore Biopharma Co., Ltd in May 2024. LakeShore Biopharma Co., Ltd was founded in 2002 and is based in Beijing, China.
Technical Analysis
CASI Pharmaceuticals
―
Kezar Life Sciences
―
Exicure
―
PolyPid
―
Rani Therapeutics Holdings
―
Ownership Overview
―
Insiders
0.39% Other Institutional Investors
99.61% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---